2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 119

Triage in Chronic Rheumatic Diseases: Quantitative Physician Estimates for Inflammation (Reversible), Damage (Irreversible), and Distress in Patients with Rheumatoid Arthritis, Osteoarthritis, and Fibromyalgia Seen in Usual Care

Health Services Research Poster I: Diagnosis, Management and Treatment Strategies

9:00AM-11:00AM: Abstract Number: 847

Troponin T and NT-Probnp Are Prognostic Cardiac Disease Biomarkers in Patients with Systemic Sclerosis without Pulmonary Arterial Hypertension

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I

9:00AM-11:00AM: Abstract Number: 558

Tuberculosis Risk Among Patients with Rheumatoid Arthritis in a United States Claims Database Initiating Abatacept and Other Biologic Disease-Modifying Antirheumatic Drugs: Analyses Using International Classification of Diseases Codes and a Published Claims Algorithm

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 382

Twelve Months after Osteoporosis Associated Fracture – Has Adequate Therapy Been Initiated?

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 163

Ultrasonographic Assessment Covers Clinical Examination in the Localization of Ankle Pathology in Rheumatoid Arthritis

Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

9:00AM-11:00AM: Abstract Number: 436

Ultrasonographic Disease Activity in Rheumatoid Arthritis Patients Who Are in Clinical Remission According to Different Remission Criteria: Should We Insist on Achieving Boolean Remission?

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 161

Ultrasonographic Evaluation of Rheumatoid Hand: Hand Disability and Disease Activity Correlation

Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

9:00AM-11:00AM: Abstract Number: 177

Ultrasonographic Joint Evaluation in Daily Practice: What Is Its Contribution to Clinical Assessment?

Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

9:00AM-11:00AM: Abstract Number: 169

Ultrasonographic Signs of Inflammation of Metatarsophalangeal Joints in Rheumatoid Arthritis Patients Who Are Treated to Target

Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

9:00AM-11:00AM: Abstract Number: 162

Ultrasonography Versus Clinical Examination in Early DMARD-Naïve Rheumatoid Arthritis – a Comparative Study of Synovitis on the Individual Joint Level

Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

9:00AM-11:00AM: Abstract Number: 441

Ultrasound Assessment of Early Response to Certolizumab Pegol Can Predict Future Response in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 168

Ultrasound Evaluation of the Efficacy of Biologic and Targeted Synthetic Dmards Toward Rheumatoid Arthritis Patients: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort in Japan

Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

9:00AM-11:00AM: Abstract Number: 190

Ultrasound Imaging with Elastography for the Medical Treatment of Dupuytren’s Contracture

Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

9:00AM-11:00AM: Abstract Number: 180

Ultrasound Quantification of Fluid Shifts in the Knees of Arthritis Patients before and after Inflation of a Pneumatic Compressive Device

Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

9:00AM-11:00AM: Abstract Number: 158

Ultrasound Score of Dominant Hand in Patients with Rheumatoid Arthritis Correlates with DAS28CRP, CDAI and SDAI but Not RAPID-3

Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].